Intradermal vaccination for Mpox immunization
Mpox has been a persistent public health issue, particularly in the Democratic Republic of the Congo (DRC) and neighbouring countries. The rising cases in the region, has caused mpox to be declared a public health emergency of international concern.
Read our white paper, which highlights how intradermal vaccination can be an attractive method for use in mass vaccination campaigns or outbreaks such as mpox, where vaccine supply may be limited.
Want to know more? Some of the topics discussed in this white paper include:
Mpox in Democratic Republic of Congo (DRC)
Reasons for ongoing challenges with Mpox in the DRC region include poor healthcare infrastructure, lack of public health knowledge on prevention methods, and conflict and political instability in the area.
Overall, in 2023, a total of 14,626 mpox cases and 654 deaths were reported in DRC. This year already has seen a significant increase compared to the previous year, with over 14,000 reported cases of the virus and 524 deaths.
Strategies to tackle the Mpox situation
To address these challenges, the World Health Organization (WHO) has developed a strategic preparedness, readiness, and response plan for mpox. This plan includes enhancing surveillance, improving diagnostic capabilities, and conducting vaccination campaigns in affected areas.
Vaccination is considered a key strategy to prevent mpox outbreaks. Given the worrying trends in the disease’s spread, WHO invites mpox vaccine manufacturers for emergency evaluation.
Intradermal vaccination for delivery of Mpox vaccine
Intradermal vaccination is particularly attractive for use in mass vaccination campaigns or outbreaks. The method offers a solution to limit the amount of vaccine dose (up to 1/5th) needed to elicit non-inferior immunogenicity to the full dose, thereby decreasing dosage volumes kept in the cold chain, and increasing vaccine availability.
VAX-ID® is an award-winning patented medical device for intradermal injections. It offers a promising solution for standardized, reliable, and user-independent injection. VAX-ID can offer a solution in ease of use and standardization of the ID injection aiding in reliable intradermal administration by health care professionals.
